SCHEMBL2849305

SCHEMBL2849305

Cl[Pt]Cl.[N].[N]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10935463 1.00
SCHEMBL22689 0.89
Water SCHEMBL28489054 0.80
Potassium SCHEMBL321057 0.80
SCHEMBL29195976 0.80
Water SCHEMBL25354626 0.80
Phosphine SCHEMBL5852309 0.80
Ammonia Solution, Strong SCHEMBL2749074 0.80
Potassium SCHEMBL10534898 0.80
Ammonia Solution, Strong SCHEMBL6043 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146088-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2026-05-28 US disclosed
US-20260132220-A1 Cysteine Engineered Antibodies and Conjugates GENENTECH, INC. (US) 2026-05-14 US disclosed
EP-4727527-A2 GRP78 TARGETED LIPOSOMAL NANOPARTICLES (TLNPS) FOR THE TREATMENT OF CANCER University of Notre Dame du Lac (US) 2026-04-22 EP disclosed
US-20250388599-A1 TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2025-12-25 US disclosed
US-12479858-B2 Macrocyclic compounds as sting agonists and methods and uses thereof LUPIN LIMITED (IN) 2025-11-25 US disclosed
EP-4622652-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER AND METABOLIC DISEASE Pretzel Therapeutics, Inc. (US) 2025-10-01 EP disclosed
WO-2024259421-A2 GRP78 TARGETED LIPOSOMAL NANOPARTICLES (TLNPS) FOR THE TREATMENT OF CANCER UNIVERSITY OF NOTRE DAME DU LAC (US) 2024-12-19 WO disclosed
US-20240309088-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2024-09-19 US disclosed
EP-4427805-A2 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE Genentech, Inc. (US) 2024-09-11 EP disclosed
EP-4004002-B1 MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF LUPIN LTD (IN) 2024-07-10 EP disclosed
WO-2009123971-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-08 WO disclosed
US-20090247567-A1 BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-10-01 US disclosed
WO-2009117277-A2 COMBINATIONS OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE GENENTECH, INC. (US) 2009-09-24 WO disclosed
WO-2009099728-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2009-08-13 WO disclosed
WO-2009099741-A1 NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS GENENTECH, INC. (US) 2009-08-13 WO disclosed
WO-2009099719-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN GENENTECH, INC. (US) 2009-08-13 WO disclosed
WO-2009097446-A1 PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2009-08-06 WO disclosed
US-20090068202-A1 Humanized Anti-CD79B Antibodies and Immunoconjugates and Methods of Use GENENTECH, INC. (US) 2009-03-12 US disclosed
WO-2009012268-A1 ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2009-01-22 WO disclosed
WO-2009012256-A1 HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE GENENTECH, INC. (US) 2009-01-22 WO disclosed